Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when COAG files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsHemab Therapeutics board member Laura Tadvalkar resigns effective immediately
Filed May 11, 2026 · Period ending May 8, 2026 · ~1 min read
Key Changes
-
medium
Dr. Laura Tadvalkar resigned from the Board of Directors effective May 8, 2026, with the company stating the departure was not due to any disagreement on operations, policies, or practices.
Item 5.02 verify on EDGAR →
Summary
Hemab Therapeutics disclosed that board member Dr. Laura Tadvalkar resigned effective May 8, 2026. The company explicitly noted her departure was not related to any disagreement with management or the board regarding operations, policies, or practices, suggesting this is a routine transition rather than a conflict-driven exit.
For retail investors, board departures can sometimes signal internal issues, but the company's clear statement that no disagreement existed reduces concern. The resignation reduces board size by one member, which may temporarily affect governance capacity depending on committee assignments.
Investors should watch for any announcement of a replacement director and whether the company provides additional context about Dr. Tadvalkar's reasons for leaving. If the board remains understaffed or additional departures follow, that could indicate deeper issues worth monitoring.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 8, 2026, Laura Tadvalkar, Ph.D., notified Hemab Therapeutics Holdings, Inc. (the “Company”) of her decision to resign as a member of the Company’s board of directors (the “Board”), effective immediately.
Dr. Laura Tadvalkar resigned from the Board of Directors effective May 8, 2026. The filing explicitly states her resignation was not related to any disagreement with the Company on any matter relating to its operations, policies or practices, suggesting this is a routine departure rather than a conflict-driven exit.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify